DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

Direct Antiviral Agents for the Treatment of Chronic HCV/HBV Co-infection Patients

This is a prospective study to determine the incidence, morbidity, mortality and predisposing factors for the reactivation of hepatitis B virus replication during direct anti-HCV treatment of HCV/HBV co-infection patients.

Patients who receive direct-acting anti-HCV treatment will be prospectively studied during 2-year period. All patients have HCV/HBV co-infection.

The inclusion/exclusion criteria and the follow up plan will be listed in following part.

Inclusion Criteria:

• HCV RNA positive,
• HBsAg positive with detectable or undetectable HBV DNA,
• Receiving pan oral direct-acting anti-HCV regimen

Exclusion Criteria:

• Pregnant or nursing female or male with pregnant female partner;
• HIV infection;
• Hematologic or biochemical parameters at Screening outside the protocol- specified requirements;
• Active or recent history (≤ 1 year) of drug or alcohol abuse;
• History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.